Effect of Melatonin Drug in Decreasing Fatigue Caused by Radiotherapy and Chemotherapy

Evaluation of the Effect of Melatonin Drug in Decreasing Fatigue Caused by Adjuvant Radiotherapy and Chemotherapy in Women with Breast Cancer: A Clinical Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180426039421N1

Enrollment

Registered

2018-06-16

Start date

2018-10-07

Completion date

Unknown

Last updated

2018-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cance

Interventions

Intervention 1: Intervention group: Oral Melatonin drug 6 mg( 2 capsule of 3 mg) every night from 3 to 7 days before the start of Adjuvant treatmentwill be used until the disease progresses. Interv

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Breast Cancer Stages I, II, III According to Pathological Reports Patients at least 18 Years Old Have Signed a Written Consent Recevieng Adjuvant Chemotherapy and Radiotherapy No Untreated Hypercalcemia No Systolic Blood Pressure Less Than 100 mm Hg No Warfarin Consumption No Methylphenidate Consumption No Sleep Pills During Melatonin Use No TSH>5/5 or <0/5 No Pregnancy or Breastfeeding

Exclusion criteria

Exclusion criteria: Expired During Treatment Stop Using Melatonin during Treatment

Design outcomes

Primary

Measure	Time frame
Fatigue severity in the BFI questionnaire. Timepoint: 4 weeks after last adjuvant treatment session. Method of measurement: Brief Fatigue Inventory( BFI) questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Kesht Pour Amlashi

Hamedan University of Medical Sciences

z.keshtpour@edu.umsha.ac.ir+98 81 3838 1076

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026